Elsevier

Journal of Infection

Volume 75, Issue 4, October 2017, Pages 373-376
Journal of Infection

Letter to the Editor
First report of Candida auris in Oman: Clinical and microbiological description of five candidemia cases

https://doi.org/10.1016/j.jinf.2017.05.016Get rights and content

Section snippets

Conflict of interest

There is no conflict of interest.

Acknowledgment

We would like to acknowledge the Mycology reference laboratory in Bristol from Public Health England for confirming the identification of the five C. auris isolates.

References (7)

There are more references available in the full text version of this article.

Cited by (71)

  • Candida auris: A new, threatening yeast

    2021, Encyclopedia of Mycology
  • Candida auris: Clinical profile, diagnostic challenge and susceptibility pattern: Experience from a tertiary-care centre in South India

    2020, Journal of Global Antimicrobial Resistance
    Citation Excerpt :

    However, only two patients (18%) were previously treated with fluconazole. This is in contrast to data from several parts of the globe that describe patients receiving antifungal therapy such as fluconazole prior to infection [20–22]. Table 4 depicts the current Indian status in the diagnosis, AFST, associated risk factors and outcome of patients infected with C. auris.

  • An overview of Candida auris in Iraq: the silent killer

    2023, Acta Scientiarum - Biological Sciences
View all citing articles on Scopus
View full text